Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.

Laurène Parrot Catherine Dong Franck Carbonnel Antoine Meyer

Published in: Alimentary pharmacology & therapeutics (2021)

In patients with CD refractory to anti-TNF, ustekinumab and vedolizumab are similarly effective in induction, but as maintenance treatment, ustekinumab appears to be more effective than vedolizumab.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
randomized controlled trial
rheumatoid arthritis
systematic review
combination therapy
replacement therapy